Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 18;80(6):1245-1246.
doi: 10.1093/cid/ciaf031.

Antiviral Trials-Navigating the Shifting Sands of a Pandemic

Beatrice Z Sim  1   2   3 , Cameron R Wolfe  1
Affiliations
Editorial

Antiviral Trials-Navigating the Shifting Sands of a Pandemic

Beatrice Z Sim et al. Clin Infect Dis. .
No abstract available

Keywords: COVID-19; antivirals; ensitrelvir.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors: B.Z.S reports no conflicts of interest. C.R.W reports advisory board work with Atea Pharmaceuticals, Invivyd and Janssen Pharamceuticals. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Comment on

References

    1. Luetkemeyer AF, Chew KW, Lacey S, et al. Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: results from the SCORPIO-HR phase 3, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2025; 80:1235–44. - PMC - PubMed
    1. Yotsuyanagi H, Ohmagari N, Doi Y, et al. Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Network Open 2024; 7:e2354991. - PMC - PubMed
    1. Hammond J, Fountaine RJ, Yunis C, et al. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. N Engl J Med 2024; 390:1186–95. - PMC - PubMed
    1. Horga A, Kuritzkes DR, Kowalczyk JJ, et al. Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19. Future Virol 2023; 18:489–500. - PMC - PubMed
    1. Horga A, Saenz R, Yilmaz G, et al. Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY). Future Virol 2023; doi: 10.2217/fvl-2023-0115 - DOI - PMC - PubMed